FGFR2 and infantile convulsions and choreoathetosis: Futibatinib was further tested in a dose expansion phase on 45 patients with cholangiocarcinoma (41 with ICCA) harboring FGFR2-aberrations, 28 of them (62%) FGFR2-fusions and 17 (38%) other FGF-FGFR aberrations.